Sun Pharma Advanced Research Company Ltd (SPARC) is currently trading at 176.90 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Sun Pharma Advanced Research Company Limited (SPARC) is a clinical-stage biopharmaceutical company focused on discovery, development and commercialization of new chemical entities and novel drug delivery systems for global markets, combining in-house translational R&D with licensing and partnership models to advance oncology, immunology and rare pediatric disease assets. SPARC reported consolidated revenue of INR 845 lakh for Q3 FY26 and nine-month consolidated revenue of INR 3,510 lakh, while recording expanded YTD losses of about INR 20,814 lakh; the company continues to rely on a promoter support letter to maintain going-concern status despite ongoing cash burn and negative equity. A significant near-term liquidity and strategic development is the tradable Rare Pediatric Disease Priority Review Voucher (PRV) associated with Sezaby’s US approval; SPARC has entered into a definitive asset purchase agreement to monetise this regulatory asset to generate non-operational liquidity and reduce near-term funding pressure. SPARC retains a focused pipeline with tangible clinical progress — Sezaby approval, Phase I completion for SCD-044 and initiation of Phase 1a for SCD-153 — while intentionally prioritizing SCD-153 and SBO-154 as anchor programs and adopting flexible NewCo and licensing structures to accelerate value realisation.

Over the past 52 weeks, Sun Pharma Advanced Research Company Ltd has traded between a low of ₹108.20 and a high of ₹289.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Sun Pharma Advanced Research Company Ltd has a market capitalization of approximately 5,946.86. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Sun Pharma Advanced Research Company Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 3.75 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 5,946.86 Cr, Sun Pharma Advanced Research Company Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Sun Pharma Advanced Research Company Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Sun Pharma Advanced Research Company Ltd is 3.75. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Sun Pharmaceutical Industries reported consolidated net profit attributable to owners of ₹2,894.79 crore for the quarter ended June 30, 2026, up 27% year-on-year.

The stock surged after a US district court granted summary judgment in SPARC’s favour in the dispute over a Priority Review Voucher linked to Sezaby.

Sun Pharma reported a consolidated net profit of ₹3,117.95 crore for the quarter ended September 2025, representing a 2.6% increase year-on-year.